Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections

J Infect Dis. 2023 Aug 31;228(5):564-575. doi: 10.1093/infdis/jiad116.

Abstract

Background: The number of exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to vaccine antigens affect the magnitude and avidity of the polyclonal response.

Methods: We studied binding and avidity of different antibody isotypes to the spike, the receptor-binding domain (RBD), and the nucleoprotein (NP) of wild-type (WT) and BA.1 SARS-CoV-2 in convalescent, mRNA vaccinated and/or boosted, hybrid immune individuals and in individuals with breakthrough cases during the peak of the BA.1 wave.

Results: We found an increase in spike-binding antibodies and antibody avidity with increasing number of exposures to infection and/or vaccination. NP antibodies were detectible in convalescent individuals and a proportion of breakthrough cases, but they displayed low avidity. Omicron breakthrough infections elicited high levels of cross-reactive antibodies between WT and BA.1 antigens in vaccinated individuals without prior infection directed against the spike and RBD. The magnitude of the antibody response and avidity correlated with neutralizing activity against WT virus.

Conclusions: The magnitude and quality of the antibody response increased with the number of antigenic exposures, including breakthrough infections. However, cross-reactivity of the antibody response after BA.1 breakthroughs, was affected by the number of prior exposures.

Keywords: SARS-CoV-2; antibodies; avidity; neutralization; omicron.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • Antibody Affinity*
  • BNT162 Vaccine / immunology
  • BNT162 Vaccine / therapeutic use
  • Breakthrough Infections* / blood
  • Breakthrough Infections* / immunology
  • COVID-19 Serological Testing
  • COVID-19* / blood
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Chlorocebus aethiops
  • Humans
  • SARS-CoV-2* / immunology
  • Vaccination
  • Vero Cells

Substances

  • Antibodies, Viral
  • BNT162 Vaccine

Supplementary concepts

  • COVID-19 breakthrough infections
  • SARS-CoV-2 variants